期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

胆固醇吸收抑制剂在血脂管理中的临床价值 被引量：3

Clinical value of cholesterol absorption inhibitors in lipid management
原文传递
导出
摘要 降胆固醇治疗是动脉粥样硬化防治的重要措施之一,临床研究表明在生活方式调整的基础上用他汀类药物可防止动脉粥样硬化的发生和发展。为了达到理想的低密度脂蛋白胆固醇(LDL-C)目标值和减少他汀类药物的副反应,胆固醇吸收抑制剂和他汀类药物的联合使用有可能在动脉粥样硬化的防治中具有一定的地位。 Cholesterol lowing treatment is one of important parts in the therapy of atherosclerosis. Clinical research demon- strated that the statins treatment combined with therapeutic lifestyle changes can prevent the genesis and development of ath- eroselerosis. Aim to achieve ideal LDL-C target level and reduce adverse effects of statins, the combination of cholesterol absorption inhihitors and statins could play a significant role in the therapy of atherosclerosis.
作者 董吁钢
机构地区 中山大学附属第一医院心血管医学部
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2014年第4期347-350,共4页 Chinese Journal of Practical Internal Medicine
关键词 胆固醇吸收抑制剂 高脂血症 他汀类药物 cholesterol absorption inhibitor hyperlipidemia statins
分类号 R589.2 [医药卫生—内分泌]
  • 相关文献

参考文献27

  • 1Shepherd J. The role of the exogenous athway in hypercholesterolaemia[J]. European Heart Journal Supplements,2001 ,3 (Supplement E) :E2 -E5.
  • 2Kesaniemi YA, Miettinen TA. Cholesterol absorption efficiency regulates plasma cholesterol level in the Finnish population [J]. Fur J Clin Invest, 1987 ,17 (5) :391 - 395.
  • 3Assmann G, Cullen P, Erbey J ,et al. Plasma sitosterol elevations are associated with an increased 'Cardiovascular Munster ( PROCAM) study[J]. Nutr Metab Cardiovasc Dis,2006,16(1):13 -21.
  • 4Matthan NR, Pencina M, LaRocque JM, et al. Alterations in cholesterol absorption! synthesis markers characterize Framingham offspring study participants with CHD [J] . J Lipid Res, 2009,50 (9) : 1927 -1935.
  • 5Miettinen TA, Gylling H, Strandberg T , et al. Baseline serum "holestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators [J ] . BMJ, 1998 ,316(7138) : 1127 - 1130.
  • 6Levine GN , Keaney IF Jr , Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms [J]. N Engl J Med,1995,332(8) :512 -52l.
  • 7Grundy SM, Cleeman JI, Merz CN , et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel ill guidelines [J]. Circulation, 2004, 110 ( 2 ) : 227 -239.
  • 8European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias , the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) [1 J. Eur Heart J, 2011 ,32( 14) : 1769 -1818.
  • 9The Collaborative Research Group for the Second Multi-center Survey of Clinical Management of Dyslipidemia in China.第二次中国临床血脂控制达标率及影响因素多中心协作研究[J].中华心血管病杂志,2007,35(5):420-427. 被引量：126
  • 10Terarnoto T, Kashiwagi A, Ishibashi S, et al. Cross-Sectional Survey to Assess the Status of Lipid Management in High-Risk Patients With Dyslipidemia , Clinical Impact of Combination Therapy With Ezetimibe[IJ . Current Therapeutic Research ,2012,73: 1 -15.

二级参考文献190

共引文献5300

同被引文献61

  • 1Marang -van de Mheen PJ, van Maarle MC, Stouthard ME. Getting insurance after genetic screening on familial hypercholesterelaemia; the need to educate both insurers and the public to increase adherence to naXional guidelines in the Netherlands [ J ]. J Epidemiol Community Health, 2002, 56 (2): 145-147.
  • 2Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial h'ypercholesterelaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atheroscleresis Society [ J]. Eur Hear J, 2013, 34 (45) : 3478 -3490a.
  • 3Ose I Diagnostic, clinical, and therapeutic aspects of familial hypercholesterolemia in children [ J ]. Semin Vasc Med, 2004, 4 (1): 51-57.
  • 4Brown MS, Ho YK, Goldstein JL. The low -density lipoprotein pathway in human fibroblasts: relation between cell surface receptor binding and endocytosis of low - density lipoprotein [ J ]. Ann N Y Acad Sci, 1976, 275: 244-257.
  • 5Vega GL, Grundy SM. In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia [ J ]. J Clin Invest, 1986, 78 (5): 1410-1414.
  • 6Broekhuizen K, Jelsma JG, van Poppel MN, et al. Is the process of delivery of an individually tailored lifestyle intervention associated with improvements in LDL cholesterol and multiple lifestyle behaviors in people with familial hypercholesterolemia? [ J ]. BMC Public Health, 2012, 12: 348.
  • 7Smith SC Jr, Allen J, Blair SN, et al. AI-IA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute [ J . Circulation, 2006, 113 (19): 2363-2372.
  • 8Moruisi KG, Oosthuizen W, Opperman AM. Phytosterols/stanols lower cholesterol concentrations in familial hypercholesterolemic subjects : a systematic review with meta - analysis [J]. J Am Call Nutr, 2006, 25 (1): 41 - 48.
  • 9Marais AD, Firth JC, Blom DJ. Homozygous familial hypereholesterolemia and its management [ J 1. Semin Vase Ned, 2004, 4 (1): 43-50.
  • 10Vuorio A, Kuoppala J, Kovanen PT, et al. Statins for children with familial hyperchalesterolemia [ J ]. Cochrane Database Syst Rev, 2010 (7) : CD006401.

引证文献3

二级引证文献11

中国实用内科杂志
2014年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部